|Mr. Habib J. Dable||CEO, Pres & Director||974.38k||N/A||1969|
|Dr. Thomas P. Maniatis||Co-Founder, Member of Scientific Advisory Board & Director Emeritus||45k||N/A||1943|
|Mr. Kevin F. McLaughlin||Sr. VP, CFO & Treasurer||591.17k||1.42M||1956|
|Dr. John D. Quisel||Exec. VP & Chief Bus. Officer||632.39k||N/A||1971|
|Mr. Sujay R. Kango||Sr. VP & Chief Commercial Officer||921.92k||N/A||1964|
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Acceleron Pharma Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 6.